DexCom chair receives RSU grant, shares withheld for taxes

DexCom Inc. Executive Chair Kevin R. Sayer reported routine equity compensation activity.

Rhea-AI Filing Summary

DexCom Inc. Executive Chair Kevin R. Sayer reported routine equity compensation activity. He received a grant of 32,749 restricted stock units (RSUs) of DexCom common stock on March 8, 2026. These RSUs are scheduled to vest on the one-year anniversary of the grant date.

The filing also shows 32,498 shares of common stock withheld by DexCom at $68.10 per share to satisfy tax withholding and remittance obligations related to RSU settlement, which the company states does not represent a sale by Sayer. After these transactions, he directly holds 409,241 shares, including 106,972 unvested RSUs with various vesting schedules through March 8, 2028.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider SAYER KEVIN R

Role Executive Chair

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	32,749	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	32,498	$68.10	$2.21M

Holdings After Transaction: Common Stock — 409,241 shares (Direct)

Footnotes (3)

1. F1. Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting on the one year anniversary of the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock.
2. F2. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person.
3. F3. Included in this number are 106,972 unvested RSUs, 32,749 of which were granted on March 8, 2026 and shall vest on March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

FAQ

What insider transactions did DexCom (DXCM) Executive Chair Kevin Sayer report?

Kevin Sayer reported a routine equity award and related tax withholding. He received 32,749 RSUs on March 8, 2026, and 32,498 shares were withheld by DexCom to cover tax obligations on RSU settlement, which the company clarifies is not a sale.

How many DexCom (DXCM) RSUs were granted to Kevin Sayer and when do they vest?

Kevin Sayer received 32,749 RSUs of DexCom common stock on March 8, 2026. The company states these RSUs vest on March 8, 2027, giving him a contingent right to receive one DexCom share for each vested RSU at settlement.

Were any DexCom (DXCM) shares sold by Kevin Sayer in this Form 4 filing?

The filing shows no open-market sale by Kevin Sayer. DexCom withheld 32,498 shares at $68.10 per share solely to satisfy tax withholding and remittance obligations for RSU settlement, and the company explicitly notes this does not represent a sale by him.

What are Kevin Sayer’s DexCom (DXCM) holdings after the reported Form 4 transactions?

After these transactions, Kevin Sayer directly holds 409,241 DexCom common shares. This total includes 106,972 unvested RSUs, which have multiple grant dates and vesting schedules running through March 8, 2027 and March 8, 2028, as described in the footnotes.

How many unvested DexCom (DXCM) RSUs does Kevin Sayer now hold and on what schedules?

Kevin Sayer holds 106,972 unvested DexCom RSUs. Of these, 32,749 were granted March 8, 2026 and vest March 8, 2027; 56,993 were granted March 8, 2025 and vest through March 8, 2028; and 17,230 were granted March 8, 2024 and vest through March 8, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/10/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SAYER KEVIN R

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chair

3. Date of Earliest Transaction (Month/Day/Year)
03/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/08/2026		A		32,749(1)	A	$0	441,739	D
Common Stock	03/08/2026		F		32,498(2)	D	$68.1	409,241(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting on the one year anniversary of the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock.

2. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person.

3. Included in this number are 106,972 unvested RSUs, 32,749 of which were granted on March 8, 2026 and shall vest on March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Kevin R. Sayer	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.